[{"AccountsPayableCurrent_0_Q2_USD":142074.0,"PaymentsForProceedsFromOtherInvestingActivities_2_Q2_USD":201250000.0,"PaymentsForRent_2_Q2_USD":10000.0,"PaymentsOfFinancingCosts_2_Q2_USD":4175530.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"PreferredStockSharesAuthorized_0_Q2_shares":1000000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockValue_0_Q2_USD":null,"PrepaidExpenseCurrent_0_Q2_USD":636426.0,"ProceedsFromIssuanceInitialPublicOffering_2_Q2_USD":201250000.0,"ProceedsFromIssuanceOfPrivatePlacement_2_Q2_USD":6025000.0,"ProceedsFromRelatedPartyDebt_2_Q2_USD":150000.0,"ProceedsFromRepaymentsOfRelatedPartyDebt_2_Q2_USD":-200000.0,"ProductionTaxExpense_1_Q2_USD":49863.0,"OtherIntangibleAssetsNet_0_Q2_USD":5000001.0,"ProductionTaxExpense_2_Q2_USD":99312.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":5000001.0,"RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1_Q2_USD":30000.0,"RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2_Q2_USD":40000.0,"RestrictedInvestmentsPercentOfNetAssets_0_Q2_pure":0.2,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-2335137.0,"SaleOfStockConsiderationReceivedOnTransaction_2_Q2_USD":201300000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":40000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":50000.0,"SharePrice_0_Q2_USD":10.0,"SharesIssuedPricePerShare_0_Q2_USD":10.0,"StockholdersEquity_0_Q2_USD":5000003.0,"StockRedeemedOrCalledDuringPeriodValue_1_Q2_USD":-2165910.0,"TaxesPayableCurrent_0_Q2_USD":98680.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q2_USD":188509380.0,"ProfitLoss_1_Q2_USD":-2165912.0,"OperatingIncomeLoss_2_Q2_USD":-2341218.0,"OperatingIncomeLoss_1_Q2_USD":-2172694.0,"NetIncomeLoss_2_Q2_USD":-2334105.0,"AccruedLiabilitiesCurrent_0_Q2_USD":1453000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":7334449.0,"Assets_0_Q2_USD":202246887.0,"AssetsCurrent_0_Q2_USD":989774.0,"AssetsHeldInTrustNoncurrent_0_Q2_USD":201257113.0,"BusinessCombinationAcquisitionRelatedCosts_2_Q2_USD":10000000.0,"Cash_0_Q2_USD":353348.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":353348.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":344548.0,"CashEquivalentsAtCarryingValue_0_Q2_USD":353000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"CommonStockValue_0_Q2_USD":188.0,"DebtInstrumentFeeAmount_0_Q2_USD":200000.0,"DeferredIncomeNoncurrent_0_Q2_USD":7043750.0,"Deposits_0_Q2_USD":250000.0,"EquityMethodInvestmentOwnershipPercentage_0_Q2_pure":0.5,"GainLossOnInvestments_2_Q2_USD":7113.0,"NetIncomeLoss_1_Q2_USD":-2165912.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-1454922.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-201250000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":203049470.0,"LiabilitiesCurrent_0_Q2_USD":1693754.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":202246887.0,"TemporaryEquityParOrStatedValuePerShare_0_Q2_USD":0.0001,"Liabilities_0_Q2_USD":8737504.0,"InterestIncomeOther_1_Q2_USD":6782.0,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":636426.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":1408000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":16042.0,"GeneralAndAdministrativeExpense_2_Q2_USD":2191906.0,"GeneralAndAdministrativeExpense_1_Q2_USD":2082831.0,"InterestIncomeOther_2_Q2_USD":7113.0,"TemporaryEquityRedemptionPricePerShare_0_Q2_USD":10.0,"Ticker":"PRDS","CIK":"1822711","name":"FS DEVELOPMENT CORP. II","OfficialName":"Pardes Biosciences Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"505269868.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20210816"}]